Study of ABBV901 for ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug called ABBV901, given alone or with another drug (bevacizumab), for people with a certain type of ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if it helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-grade serous ovarian, fallopian tube, or primary peritoneal cancer that cannot be removed by surgery or has spread.
- Your cancer is resistant to platinum chemotherapy (it grew back within 6 months after your last platinum treatment) or you cannot receive platinum therapy.
- You have had no more than 2 prior treatments since your cancer became platinum-resistant.
- If you are in the backfill group, you must agree to have two tumor biopsies (one before and one during treatment).
- You have not received any prior therapy with an antibody-drug conjugate that contains a topoisomerase inhibitor.
- You have no history of interstitial lung disease or pneumonitis that needed steroids, and no current signs of it on a CT scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination therapy (SYS6041 plus another drug) for women with recurrent ovarian cancer. It is for those whose cancer has come back after platinum chemotherapy, and who have not had too many previous treatments. The goal is to see if the combination can shrink tumors or slow disease progression.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This Phase 2 trial compares two standard doses of bevacizumab (a medicine that targets blood supply to tumors) added to chemotherapy in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. It’s for ovarian cancers that have returned or grown again soon after prior platinum chemotherapy, with the goal of improving control of the disease.
This study tests a new medicine called TUB-040, given together with standard ovarian cancer drugs like carboplatin and bevacizumab. It is for women with ovarian cancer that has returned after responding to platinum-based chemotherapy and is growing again. The goal is to see if this combination can help control the cancer.
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
This study tests a new drug, COM701, for people with ovarian cancer that came back after treatment but still responds to platinum-based chemotherapy. It aims to see if COM701 is safe and effective for patients who have already tried several treatments.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.